Cargando…

Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome

Chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS) has a negative impact on the quality of life, and its etiology still remains unknown. Although many treatment protocols have been evaluated in CP/CPPS, the outcomes have usually been disappointing. Botulinum neurotoxin A (BoNT-A), produced...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chien-Hsu, Tyagi, Pradeep, Chuang, Yao-Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832516/
https://www.ncbi.nlm.nih.gov/pubmed/31614473
http://dx.doi.org/10.3390/toxins11100586
_version_ 1783466191327592448
author Chen, Chien-Hsu
Tyagi, Pradeep
Chuang, Yao-Chi
author_facet Chen, Chien-Hsu
Tyagi, Pradeep
Chuang, Yao-Chi
author_sort Chen, Chien-Hsu
collection PubMed
description Chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS) has a negative impact on the quality of life, and its etiology still remains unknown. Although many treatment protocols have been evaluated in CP/CPPS, the outcomes have usually been disappointing. Botulinum neurotoxin A (BoNT-A), produced from Clostridium botulinum, has been widely used to lower urinary tract dysfunctions such as detrusor sphincter dyssynergia, refractory overactive bladder, interstitial cystitis/bladder pain syndromes, benign prostatic hyperplasia, and CP/ CPPS in urology. Here, we review the published evidence from animal models to clinical studies for inferring the mechanism of action underlying the therapeutic efficacy of BoNT in CP/CPPS. Animal studies demonstrated that BoNT-A, a potent inhibitor of neuroexocytosis, impacts the release of sensory neurotransmitters and inflammatory mediators. This pharmacological action of BoNT-A showed promise of relieving the pain of CP/CPPS in placebo-controlled and open-label BoNT-A and has the potential to serve as an adjunct treatment for achieving better treatment outcomes in CP/CPPS patients.
format Online
Article
Text
id pubmed-6832516
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68325162019-11-25 Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome Chen, Chien-Hsu Tyagi, Pradeep Chuang, Yao-Chi Toxins (Basel) Review Chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS) has a negative impact on the quality of life, and its etiology still remains unknown. Although many treatment protocols have been evaluated in CP/CPPS, the outcomes have usually been disappointing. Botulinum neurotoxin A (BoNT-A), produced from Clostridium botulinum, has been widely used to lower urinary tract dysfunctions such as detrusor sphincter dyssynergia, refractory overactive bladder, interstitial cystitis/bladder pain syndromes, benign prostatic hyperplasia, and CP/ CPPS in urology. Here, we review the published evidence from animal models to clinical studies for inferring the mechanism of action underlying the therapeutic efficacy of BoNT in CP/CPPS. Animal studies demonstrated that BoNT-A, a potent inhibitor of neuroexocytosis, impacts the release of sensory neurotransmitters and inflammatory mediators. This pharmacological action of BoNT-A showed promise of relieving the pain of CP/CPPS in placebo-controlled and open-label BoNT-A and has the potential to serve as an adjunct treatment for achieving better treatment outcomes in CP/CPPS patients. MDPI 2019-10-11 /pmc/articles/PMC6832516/ /pubmed/31614473 http://dx.doi.org/10.3390/toxins11100586 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chen, Chien-Hsu
Tyagi, Pradeep
Chuang, Yao-Chi
Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome
title Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome
title_full Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome
title_fullStr Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome
title_full_unstemmed Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome
title_short Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome
title_sort promise and the pharmacological mechanism of botulinum toxin a in chronic prostatitis syndrome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832516/
https://www.ncbi.nlm.nih.gov/pubmed/31614473
http://dx.doi.org/10.3390/toxins11100586
work_keys_str_mv AT chenchienhsu promiseandthepharmacologicalmechanismofbotulinumtoxinainchronicprostatitissyndrome
AT tyagipradeep promiseandthepharmacologicalmechanismofbotulinumtoxinainchronicprostatitissyndrome
AT chuangyaochi promiseandthepharmacologicalmechanismofbotulinumtoxinainchronicprostatitissyndrome